Moneycontrol PRO
UPCOMING EVENT:Moneycontrol Pro & Espresso (A Sharekhan Company) in association with Intrazon 2.0 bring to you India’s Largest Retail Intraday Traders Online Conference. Learn 12 Amazing Strategies from 12 Intraday Traders @ Rs. 600/-. Register Now!

Buy Ipca Laboratories; target of Rs 2560: ICICI Direct

ICICI Direct is bullish on Ipca Laboratories has recommended buy rating on the stock with a target price of Rs 2560 in its research report dated August 07, 2021.

August 10, 2021 / 11:41 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

ICICI Direct's research report on Ipca Laboratories


Ipca is a fully integrated pharma company manufacturing over 350 formulations (73% of revenues) and 80 APIs (27% of revenues) with exports contributing 48% of revenues. It is a leading supplier of APIs like atenolol (antihypertensive), chloroquine and artemisinin derivatives (antimalarial), furosemide (diuretic), and pyrantel salts (anthelmintic) Major therapeutic segments include pain management cardiovascular and anti-diabetics, anti-malarials which together account for 75% of the revenues


Outlook


We change our view from HOLD to BUY on this stock due to good traction in domestic formulations and growth in the medium term We value Ipca at Rs 2560 i.e. 25x P/E on FY23E EPS


For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Aug 10, 2021 11:41 am

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark